|
Select publications
Alberts SR et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 1996;78(4):764-72. Abstract
Allred DC et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11(2):155-68. Abstract
Bardou VJ et al. Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 2003;21(10):1973-9. Abstract
Chebil G et al. Comparison of immunohistochemical and biochemical assay of steroid receptors in primary breast cancer — clinical associations and reasons for discrepancies. Acta Oncol 2003;42(7):719-25. Abstract
Diaz LK et al. Interobserver agreement for estrogen receptor immunohistochemical analysis in breast cancer: A comparison of manual and computer-assisted scoring methods. Ann Diagn Pathol 2004;8(1):23-7. Abstract
Diaz LK, Sneige N. Estrogen receptor analysis for breast cancer: Current issues and keys to increasing testing accuracy. Adv Anat Pathol 2005;12(1):10-19. Abstract
Elledge RM et al. Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: A Southwest Oncology Group Study. Int J Cancer 2000;89(2):111-7. Abstract
Fisher B. Treatment of primary breast cancer with L-PAM/5-FU and tamoxifen: An interim report. Breast Cancer Res Treat 1983;3(Suppl):7-17. Abstract
Fisher B et al. Adjuvant chemotherapy with and without tamoxifen in the treatment of primary breast cancer: 5-year results from the National Surgical Adjuvant Breast and Bowel Project Trial. J Clin Oncol 1986;4(4):459-71. Abstract
Fisher B et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983;1(4):227-41. Abstract
Fisher B et al. Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Res Treat 1983;3(4):355-64. Abstract
Fisher B et al. Treatment of primary breast cancer with chemotherapy and tamoxifen. N Engl J Med 1981;305(1):1-6. Abstract
Harvey JM et al. Estrogen receptor status by immunohistochemistry is superior to the ligandbinding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17(5):1474-81. Abstract
Mohsin SK et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: A validation study. Mod Pathol 2004;17(12):1545-54. Abstract
Takei H et al. Predictive value of estrogen receptor status as assessed by ligand-binding assay in patients with early-stage breast cancer treated with breast conserving surgery and radiation therapy. Oncol Rep 2002;9(2):375-8. Abstract
Wells CA et al; European Working Group for Breast Screening Pathology. Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union — an interlaboratory study. Virchows Arch 2004;445(2):119-28. Abstract
Yoshida N et al. Prediction of prognosis of estrogen receptor-positive breast cancer with combination of selected estrogen-regulated genes. Cancer Sci 2004;95(6):496-502. Abstract
Select publications
Cobleigh M et al. Tumor gene expression predicts distant disease-free survival (DDFS) in breast cancer patients with 10 or more positive nodes: High throughput RT-PCR assay of paraffinembedded tumor tissues. Proc ASCO 2003;Abstract 3415.
Cronin M et al. Measurement of gene expression in archival paraffin-embedded tissues: Development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164(1):35-42. Abstract
Esteban J et al. Tumor gene expression and prognosis in breast cancer: Multi-gene RT-PCR assay of paraffin-embedded tissue. Proc ASCO 2003;Abstract 3416.
Fisher B et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320(8):479-84. Abstract
Fisher B et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001;93(9):684-90. Abstract
Fisher B et al. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 1997;89(22):1673-82. Abstract
Fisher B et al. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: Updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials. J Natl Cancer Inst 2004;96(24):1823-31. Abstract
Fisher B et al. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: Longterm findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 2004;364(9437):858-68. Abstract
Habel LA et al. A large case-control study of gene expression and breast cancer death in the Northern California Kaiser Permanente population. Breast Cancer Res Treat 2004;88(1 Suppl 1):118; Abstract 3019.
Paik S. Expression of the 21 genes in the Recurrence Score assay and prediction of clinical benefit from tamoxifen in NSABP study B-14 and chemotherapy in NSABP study B-20. Presentation. San Antonio Breast Cancer Symposium, 2004;Abstract 24.
Paik S. Multi-gene RT-PCR assay for predicting recurrence in node negative breast cancer patients NSABP studies B-20 and B-14. Presentation. San Antonio Breast Cancer Symposium, 2003;Abstract 16.
Paik S et al. Risk classification of breast cancer patients by the Recurrence Score assay: Comparison to guidelines based on patient age, tumor size, and tumor grade. Breast Cancer Res Treat 2004;88 (1 Suppl 1):118;Abstract 104.
Piccart MJ et al. Multi-center external validation study of the Amsterdam 70-gene prognostic signature in node negative untreated breast cancer: Are the results still outperforming the clinicalpathological criteria? San Antonio Breast Cancer Symposium, 2004;Late Abstract 38.
Van de Vijver MJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347(25):1999-2009. Abstract
Van ’t Veer LJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):530-6. Abstract
Select publications
Aapro MS. Long-term implications of bone loss in breast cancer. Breast 2004;13(Suppl 1):29-37. Abstract
Baum M. Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 Trial. Cancer Control 2004;11(4):217-21. Abstract
Boccardo F. Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. Breast Cancer Res Treat 2003;82(Suppl 1):6;Abstract 3.
Boccardo F. Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer. Clin Breast Cancer 2004;5(Suppl 1):13-7. Abstract
Choueiri TK et al. Role of aromatase inhibitors in the treatment of breast cancer. Clin Ther 2004; 26(8):1199-214. Abstract
Chung CT, Carlson RW. Adjuvant aromatase inhibitors following tamoxifen for early-stage breast cancer in postmenopausal women: What do we really know? Clin Breast Cancer 2004;5(Suppl 1):18-23. Abstract
Coleman R, on behalf of the ATAC Trialists' Group. Association between prior chemotherapy and the adverse event (AE) profile of adjuvant anastrozole (A) or tamoxifen (T): A retrospective analysis from the ATAC trial. Journal of Clinical Oncology 2004;22(14S);Abstract 767.
Coombes RC et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350(11):1081-92. Abstract
Coombes RC et al. The Intergroup Exemestane Study: A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen – updated survival analyses. Breast Cancer Res Treat 2004;88(Suppl 1):7;Abstract 3.
Distler W, on behalf of the ATAC Trialists' Group. Impact of age on the gynecologic adverse event (AE) profile of anastrozole (A) or tamoxifen (T) in the ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial. Journal of Clinical Oncology 2004;22(14S);Abstract 770.
Dixon JM et al. Anastrozole demonstrates clinical and biological effectiveness in oestrogen receptorpositive breast cancers, irrespective of the erbB2 status. Eur J Cancer 2004;40(18):2742-7. Abstract
Dowsett M, on behalf of the ATAC Trialists’ Group. Analysis of time to recurrence in the ATAC (arimidex, tamoxifen, alone or in combination) trial according to estrogen receptor and progesterone receptor status. Breast Cancer Res Treat 2003;82(Suppl 1):7;Abstract 4.
Fallowfield L et al. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22(21):4261-71. Abstract
Goss PE et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003;349(19):1793-802. Abstract
Grana G. Shifting paradigms in hormonal therapy for breast cancer. Cancer Biol Ther 2004;3(9):797- 805. Abstract
Harwood KV. Advances in endocrine therapy for breast cancer: Considering efficacy, safety, and quality of life. Clin J Oncol Nurs 2004;8(6):629-37. Abstract
Howell A, on behalf of the ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Howell A, Dowsett M. Endocrinology and hormone therapy in breast cancer: aromatase inhibitors versus antioestrogens. Breast Cancer Res. 2004;6(6):269-74. Abstract
Jakesz R, on behalf of the ABCSG. Benefits of switching postmenopausal women with hormonesensitive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: Combined results from 3,123 women enrolled in the ABCSG Trial 8 and the ARNO 95 Trial. Breast Cancer Res Treat 2004;88(Suppl 1):7;Abstract 2.
Janicke F. Are all aromatase inhibitors the same? A review of the current evidence. Breast 2004; (13Suppl 1):10-8. Abstract
Jones KL, Buzdar AU. A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 2004 Sep;11(3):391-406. Abstract
Locker GY, on behalf of the ATAC Trialists' Group. Cost-utility analysis of anastrozole versus tamoxifen as primary adjuvant therapy in postmenopausal women with early breast cancer from a US healthcare system perspective: The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial. Breast Cancer Res Treat 2004;(88Suppl 1):105; Abstract 2085.
Mackey JR, Joy AA. Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer 2005; [Epub ahead of print]. Abstract
Tobias JS. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: Implications for treatment and prevention. Ann Oncol 2004;15(12):1738-47. Abstract
|
